Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Marian Nakada
AddedMar 31, 2024
UpdatedMay 31, 2026
Marian Nakada

Marian Nakada

Board Member, New England Venture Capital Association

CrunchbaseLinkedIn

Marian Nakada's Career

New England Venture Capital Association
New England Venture Capital Association

Boston, MA, US

Board Member· Board
Navitor Pharmaceuticals
Navitor Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Ribon Therapeutics
Ribon Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Marian Nakada's Career

New England Venture Capital Association
New England Venture Capital Association
Investment FirmInvestment Firm131902Boston, MA, US
Board Member· Board

Leadership at New England Venture Capital Association

Lily LymanLily LymanBoard Member
Neil ExterNeil ExterBoard Member
Jeff BussgangJeff BussgangBoard Member
Stephen KrausStephen KrausBoard Member
Kevin BittermanKevin BittermanBoard Member
Colleen CuffaroColleen CuffaroBoard Member
Navitor Pharmaceuticals
Navitor Pharmaceuticals
Series B$98.2M362010Cambridge, MA, US
Board Member· Board

Leadership at Navitor Pharmaceuticals

Alan CraneAlan CraneBoard Member
George P. VlasukGeorge P. VlasukBoard Member
Jean-François FormelaJean-François FormelaBoard Member
Paul A. FriedmanPaul A. FriedmanBoard Member
Vinzenz PloererVinzenz PloererBoard Member
Thomas E HughesThomas E HughesBoard Member
Ribon Therapeutics
Ribon Therapeutics
Series B$259M572015Cambridge, MA, US
Board Member· Board

Leadership at Ribon Therapeutics

Jon RootJon RootBoard Member
Jeff GoaterJeff GoaterBoard Member
Peter SvennilsonPeter SvennilsonBoard Member
Jodie MorrisonJodie MorrisonBoard Member
Paul ChangPaul ChangCo-Founder
Jim AudiaJim AudiaBoard Member

Similar to Ribon Therapeutics

RibometrixRibometrixGreenville, NC, USDrug Discoveryest. 2014RibometrixGreenville, NC, US · est. 2014

Ribometrix, a US-based biotech firm, leverages 3D RNA analysis for novel drug discovery.

Series A · $45.3M29
ENB TherapeuticsENB TherapeuticsNew York City, NY, USCancer Therapeuticsest. 2015ENB TherapeuticsNew York City, NY, US · est. 2015

ENB Therapeutics, Inc.: A US-based biopharmaceutical firm developing novel inhibitors to treat cancers.

Series A · $8.2M8
Redona TherapeuticsRedona TherapeuticsWatertown, MA, USCancer Treatmentest. 2016Redona TherapeuticsWatertown, MA, US · est. 2016

Redona Therapeutics: Advancing small molecule therapies for cancer via ncRNA modulation.

Series A · $66.8M24

Marian Nakada's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · Kakao

People Similar to Marian Nakada

Gilad GlickGilad GlickBoard Member · Beta BionicsWilliam CohnWilliam CohnCo-Founder · Houston Medical RoboticsPeter FasoloPeter FasoloBoard Member · Tufts UniversitySalma JuttSalma JuttBoard Member · American Heart AssociationMichael BoiceMichael BoiceCo-Founder · RepairogenMike KleinMike KleinBoard Member · Icad